Our May volume is out!🎉

*COUNTDOWN Report - #ClimateCrisis 🌡️
*Editorial: #breastcancer
*Comment: #schoolshootings ; #mastectomy
*Articles: #tuberculosis 🇵🇪, #syphilis 🇨🇦, #covid 🇨🇱,RCT #ASD , #liverdisease 🇧🇷
And more: bit.ly/3o7kcVC

Our June issue is out now at thelancet.com/gastrohep!

Content: management of IBS, loss of response to anti-TNF in Crohn’s, HCC surveillance in Africa, the environmental impact of gastroenterology, liver transplant for ACLF, MASLD, viral hepatitis + more

#GITwitter #LiverTwitter

ICYMI:

KEYNOTE-412: Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, phase 3 trial thelancet.com/journals/lanon…
#headandneckcancer

Online first:

Results from DESTINY-PanTumor01:
#Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations: an international, phase 2 study thelancet.com/journals/lanon…

Spain has several regional differences when offering #Cancer care. For this reason, resources, such as a National Cancer Registry in the country are a major necessity

Learn more about cancer inequalities in Spain and Europe - europeancancer.org/pulse

“Cancer prevention is in our hands“

Dr. Jesús García-Foncillas, President of Fundación ECO kick-started the launch of #TimeToAccelerate #ToguetherAgainstCancer in Spain

We are addressing #Cancer prevention, screening and the workforce crisis

Learn more➡️europeancancer.org/manifesto/reso…

For the full paper see here: thelancet.com/journals/lanon…

Also in the May issue:

Results from the Natalie Trial: Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma: a single-arm, phase 2 trial thelancet.com/journals/lanon…
#rarecancer

ICYMI - now in our May issue:

Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial thelancet.com/journals/lanon…
#rarecancer

Yet more bad news in the UK’s healthcare system: NHS problems leave new doctors without jobs bbc.co.uk/news/health-68…

Great to see the TRIANGLE trial finally out The Lancet: RCT of ibrutinib added to first line chemotherapy for patients with mantle cell lymphoma
thelancet.com/journals/lance…

+ Commentary: Does TRIANGLE take down transplantation in mantle cell lymphoma?thelancet.com/journals/lance…
#lymsm

Don’t miss this session at #asco24 - North American launch of The Lancet Commission in Women, Power, and Cancer. @asco Ophira Ginsburg

News: Biden administration delays long-awaited ban on #mentholcigarettes thelancet.com/journals/lanon…

News: Inadequate government #funding for UK #hospices affects #palliativecare thelancet.com/journals/lanon…

📰May issue out now! bit.ly/3P2PVls

🫁 Read content on septic shock, early mobilisation in the ICU, #NSCLC , ventilator associated #pneumonia , pulmonary sarcoidosis and more!

📑Editorial on barriers and ethical considerations in lung transplant: tinyurl.com/mrxsbmwc

Now in our May issue:

Results from CheckMate 358:

Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer: a phase 1–2, open-label, multicohort trial thelancet.com/journals/lanon…

Online First:

Results from EUROCARE-6: Long-term survival for lymphoid neoplasms and national health #expenditure : a retrospective, population-based study thelancet.com/journals/lanon…

#leusm #lymsm

Global study in The Lancet Public Health reveals stark differences in major causes of disease burden between females and males, underscoring the need for gender-responsive approaches to health. hubs.li/Q02vFZ2m0

Great talk by Julie Gralow on how ASCO and Common Sense Oncology have shared values and highlighting the opportunities for collaboration.